![Crystalline forms of (S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of making](/docs/US/2024-06-04/US11999744B2/abs.jpg.600x600.jpg)
- Patent Title: Crystalline forms of (S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of making
-
Application No.: US18543793Application Date: 2023-12-18
-
Publication No.: US11999744B2Publication Date: 2024-06-04
- Inventor: Joshua D. Waetzig , Gordon Wilkie
- Applicant: Blueprint Medicines Corporation
- Applicant Address: US MA Cambridge
- Assignee: Blueprint Medicines Corporation
- Current Assignee: Blueprint Medicines Corporation
- Current Assignee Address: US MA Cambridge
- Agency: McCarter & English, LLP
- Agent Wei Song
- The original application number of the division: US17153727 2021.01.20
- Main IPC: C07D487/04
- IPC: C07D487/04 ; A61P17/00 ; A61P35/00
![Crystalline forms of (S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of making](/abs-image/US/2024/06/04/US11999744B2/abs.jpg.150x150.jpg)
Abstract:
Crystalline Forms of Compound (I):
pharmaceutically acceptable salts thereof and solvates of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating disorders and conditions associated with oncogenic KIT and PDGFRA alterations using the same, and methods for making Compound (I) and crystalline forms thereof are also disclosed.
pharmaceutically acceptable salts thereof and solvates of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating disorders and conditions associated with oncogenic KIT and PDGFRA alterations using the same, and methods for making Compound (I) and crystalline forms thereof are also disclosed.
Public/Granted literature
Information query
